NASDAQ$VYNE
VYNE Therapeutics INC · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Reported year-end financial results and provided a corporate update.
VYNE Therapeutics reported financial results for the fourth quarter and year ended December 31, 2021. The company focused on developing novel therapies for immuno-inflammatory conditions and completed the divestiture of their topical minocycline MST franchise.
- Completed the divestiture of topical minocycline MST franchise in January.
- Reported positive Phase 1b safety data for FMX114.
- Released promising preclinical data for InhiBET inhibitor platform.
- Plan to report Phase 2a safety and efficacy results in the second quarter.
Headline financials
Revenue & EPS history
VYNE · Revenue · Quarterly
$2.29M
Revenue by segment
VYNE · $86K total across 1 segment · Q1 2026
- Royalty revenues$86K—100.0%
Forward guidance
VYNE plans to report Phase 2a safety and efficacy results in the second quarter, initiate their first in-human clinical study for VYN201 in the second half of the year, followed by exercising of the option and an IND filing for VYN202.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2021
-1.0%
Avg return
Earnings day
-2.1%
Avg return
5 days after
-10.8%
Avg return
30 days after
52%
17 / 33 earnings
Positive
+23.0%
Q4 2021
Best reaction
-38.4%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.0% | — | — | |
| Q4 2025 | +1.0% | -0.2% | -0.5% | |
| Q2 2025 | +0.6% | -4.3% | -10.6% | |
| Q1 2025 | -2.4% | -20.0% | -28.1% | |
| Q4 2024 | -2.5% | -21.3% | -34.7% | |
| Q3 2024 | +1.0% | -4.2% | -14.4% | |
| Q2 2024 | +8.8% | +8.2% | +7.6% | |
| Q1 2024 | -1.8% | +6.3% | -17.3% | |
| Q4 2023 | -4.7% | -3.4% | +31.8% | |
| Q3 2023 | +1.7% | +11.4% | -23.1% | |
| Q2 2023 | -11.8% | -13.7% | -26.7% | |
| Q1 2023 | +20.9% | +17.9% | -11.9% | |
| Q4 2022 | -14.7% | -21.2% | -11.1% | |
| Q3 2022 | +9.7% | +0.0% | -15.4% | |
| Q2 2022 | +5.3% | +12.5% | -4.6% | |
| Q1 2022 | +5.0% | +8.2% | +27.2% | |
| Q4 2021 | +23.0% | +28.7% | -8.0% | |
| Q3 2021 | -1.5% | -5.9% | +10.3% | |
| Q2 2021 | -38.4% | -42.9% | -45.7% | |
| Q1 2021 | -19.7% | -24.9% | -15.4% | |
| Q4 2020 | -9.7% | -6.5% | -6.5% | |
| Q3 2020 | -2.6% | +0.6% | -1.2% | |
| Q2 2020 | -12.5% | -12.2% | -26.8% | |
| Q1 2020 | -7.2% | -13.3% | +7.2% | |
| Q4 2019 | +5.8% | +42.6% | -9.3% | |
| Q3 2019 | +4.4% | +2.6% | -21.3% | |
| Q2 2019 | -8.7% | -16.4% | +29.8% | |
| Q1 2019 | -1.3% | -2.3% | -4.5% | |
| Q4 2018 | +0.5% | +0.2% | -7.3% | |
| Q3 2018 | +1.7% | +0.0% | -17.8% | |
| Q2 2018 | +3.4% | -2.7% | -5.9% | |
| Q1 2018 | +9.2% | +7.2% | -11.9% | |
| Q4 2017 | +4.8% | +2.9% | -78.1% | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro